Anneli B.
- Country
- Sweden
- Department
- Akademiskt Specialistcentrum, Centrum för Diabetes
Research Overview
- Phase I/II Study of AdaptNK Cell Therapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Evaluation of Diamyd (Recombinant Human Glutamate Decarboxylase 2) and Colecalciferol in Preserving Beta Cell Function in HLA DR3-DQ2 Positive Type 1 Diabetes
- Evaluation of HLA-DR3DQ2 Influence on LADA Status and Immune Parameters Post Intralymphatic Glutamate Decarboxylase 2, Human, Recombinant Treatment
Data & Insights
Has run more than one trial at 5 of 52 partner sites.
Specializations
Diabetes Research
This investigator specializes in researching therapeutic approaches for autoimmune diabetes conditions, with particular focus on Type 1 diabetes mellitus and Latent Autoimmune Diabetes in Adults (LADA).
- Beta cell function preservation
- Glycemic control optimization
- Autoimmune diabetes treatment
Their research encompasses studies on novel therapeutic interventions for recently diagnosed diabetes patients.
Immunological Studies
The investigator focuses on immunological aspects of diabetes, particularly studying the relationship between HLA genotypes and treatment responses in diabetes patients.
- HLA DR3-DQ2 haplotype research
- GAD65 antibody studies
- Immune system modulation
Their work includes investigating genetic markers and immunological responses in diabetes treatment.
Therapeutic Innovation
The investigator evaluates innovative treatment approaches including intranodal administration techniques and novel therapeutic compounds for diabetes management.
- Long-term treatment outcomes
- Metabolic control assessment
- Treatment response evaluation
Their research examines therapeutic efficacy in different patient populations with autoimmune diabetes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.